<

UCB (EBR:UCB) UCB Media Room: UCB strengthens its gene therapy activities

Transparency directive : regulatory news

12/11/2020 07:05
https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513= 9PTmAm2ORJ-2Fb7C-2B6en6pyWaKtUsL47mDeuiAEn-2B-2BYyMQThdC-2BaRE3nNNUMzB757Yb= gDJDh5u1WL6MPhCJfZLDKAvPoXcjDyF0UWxm-2F45lec_xDPID0vOuylFAU8fv4e60wei4JxqEG= BdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2= X9c9g1wa7AX2nOjLdtuLJFh1t96PZpeudGCMKgHESdiSWtHQCLvgp4szWoY22W6E7ZH8PYYDjwA= plKHXgXDO2qvXqn-2F0coBhTlEueO-2BIBv6n7Vp5Z6FB8mtHiH3aqq7PQ3RVTYlmE5zWtPvh4a= iV-2F-2F0K2TLp8tKswHb5ueZZrGzy0lfbcB-2BIcFqsY8MBJZUNEIi4aHiG50zCQQsCgQH01FV= blmAROpDVPFhZduTJO5Mq6YCUtF8ZCu-2FDScMpL55arF6P3kjA-3D ** UCB strengthens its gene therapy activities with additional pipeline pro= grams, capabilities and platforms ------------------------------------------------------------ =C2=B7 Acquisition of Handl Therapeutics BV augments UCB=E2=80=99s existing= early gene therapy pipeline with two research programs, a proprietary aden= o-associated virus (AAV) capsid technology platform and capabilities=C2=A0 =C2=B7 New R&D collaboration with Lacerta Therapeutics provides access to a= novel gene therapy program and proprietary AAV capsids =C2=B7 Gene therapy investment strengthens UCB=E2=80=99s capabilities to di= scover and develop differentiated solutions with unique outcomes for patien= ts BRUSSELS, BELGIUM (12th November 2020, 07:00 CET) =E2=80=93 UCB today annou= nced the acquisition of Handl Therapeutics BV, a rapidly growing and transf= ormative gene therapy company based in Leuven, Belgium and a new collaborat= ion with Lacerta Therapeutics, a Florida based clinical stage gene therapy = company. The new acquisition and collaboration will together serve to rapid= ly accelerate UCB=E2=80=99s ambition in gene therapy. UCB has a vision to move from symptomatic treatments to disease modificatio= n and eventually towards a cure. AAV-mediated gene therapy offers to delive= r that potential and drive a fundamental change in how diseases are treated= with the ability to remove or add disease-related proteins with a single t= reatment. A vast array of diseases are amenable to gene therapy and UCB is = embracing this modality to expand its capabilities and ultimately transform= the lives of patients with severe diseases. =E2=80=9CHandl Therapeutics BV was formed with the goal of harnessing today= =E2=80=99s new frontiers in science and technology, and delivering transfor= mative and advanced medicines to patients,=E2=80=9D said Professor Michael = Linden, Founder and Chief Scientific Officer at Handl Therapeutics BV. =E2= =80=9CKnowing that UCB shares this goal too gives me great confidence that = our combined resources and expertise will provide the best possible chance = of making this a reality and I am happy that we are joining the UCB family.= =E2=80=9D Founded in 2019, Handl Therapeutics BV has a vision to deploy the power of = disease modifying in vivo gene therapy to treat complex neurodegenerative d= iseases through AAV capsid technology. Operating in a highly collaborative = manner, Handl Therapeutics BV has built a strong international network to a= ccess global capabilities and expertise. To this end, it combines state of = the art technology platforms and scientific advances licenced from KU Leuve= n (Belgium), Centre for Applied Medical Research (CIMA Universidad de Navar= ra, Spain), University of Chile (Chile) and King=E2=80=99s College London (= UK) to address unmet medical needs.=C2=A0 Florent Gros, Handl Therapeutics BV Founder and Chief Executive Officer sai= d, =E2=80=9CUCB=E2=80=99s global footprint and scientific expertise in neur= odegenerative diseases, coupled with our shared cultures of scientific adva= ncement and commitment to patients, creates an exceptional environment in w= hich we can accelerate the development of gene therapies and change patient= s=E2=80=99 lives.=E2=80=9D The Handl Therapeutics team will continue to be based in Leuven, Belgium, a= nd will work very closely with UCB=E2=80=99s international research teams.= =C2=A0 In addition to the Handl Therapeutics BV acquisition, today=E2=80=99s annou= ncement of a new collaboration with Lacerta Therapeutics underlines UCB=E2= =80=99s strategic focus in gene therapy to fulfil its Patient Value Ambitio= n. These transactions build upon the strategic acquisition of Element Genom= ics, Inc. (acquired in 2018) that strengthened UCB=E2=80=99s genomics and e= pigenomics research platforms aiding the identification of novel drug targe= ts.=C2=A0 Founded in 2017, and a spin-off from the University of Florida, Lacerta The= rapeutics=E2=80=99 mission is to make AAV-based therapies available for all= patients with rare and serious neurological disorders. The research collab= oration and licensing agreement with UCB will focus on a central nervous sy= stem (CNS) disease with a high unmet need. Lacerta Therapeutics will lead r= esearch, preclinical activities and the early manufacturing process develop= ment, while UCB will complete IND-enabling studies, manufacturing and clini= cal development. This new collaboration will allow UCB to access Lacerta Th= erapeutics=E2=80=99 expertise in AAV-based CNS targeted gene therapies, for= tifying UCB=E2=80=99s ability to produce effective treatments for neurodege= nerative diseases.=C2=A0 =E2=80=9CAt Lacerta Therapeutics, we have dedicated our careers to the deve= lopment of AAV gene therapy platforms and it remains our mission to advance= these platforms and develop novel therapeutics for patients with neurodege= nerative disorders,=E2=80=9D said Dr. Edgardo Rodr=CE=AFguez-Lebr=C3=B2n, P= resident and Chairman of the Board at Lacerta. =E2=80=9CWe are looking forw= ard to entering a new era, working in partnership with UCB. Our hope is tha= t our combined expertise will lead to significant advances in identifying t= reatments for orphan CNS diseases.=E2=80=9D Dhavalkumar Patel, UCB=E2=80=99s Chief Scientific Officer said, =E2=80=9CUC= B=E2=80=99s ambition for patients relies on our ability to innovate and del= iver highly differentiated medicines. The acquisition of Handl Therapeutics= BV and the new partnership with Lacerta Therapeutics offers us the potenti= al to drive a fundamental change in how diseases are treated, by moving us = from treating symptoms to disease modification and eventually towards a cur= e.=E2=80=9D He added, =E2=80=9CWe are delighted to be able to welcome a ric= h diversity of talent and expertise from both Handl Therapeutics BV and Lac= erta Therapeutics. With their deep and wide-ranging knowledge, novel gene t= herapy platforms and drive for innovation, I am confident that together we = will transform the lives of people living with severe neurodegenerative dis= eases.=E2=80=9D This acquisition and new collaboration do not impact UCB=E2=80=99s financia= l outlook for 2020. About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With more than 7,600 people in= approximately 40 countries, the company generated revenue of =E2=82=AC 4.9= billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow = us on Twitter: @UCB_news. About Handl Therapeutics BV The vision of Handl Therapeutics is to deploy the power of disease modifyin= g in vivo gene therapy to treat complex neurodegenerative diseases to begin= addressing significant unmet medical needs in healthcare. The innovative b= usiness model is based on a highly integrative approach that is built on ti= ght links with an international network of academic partners. Handl Therape= utics goal is to build a streamlined business that is designed to deliver t= ransformative advanced medicines to the market. About Lacerta Therapeutics Lacerta Therapeutics Inc (www.lacertatx.com) is a clinical-stage gene thera= py company that is leveraging its proprietary adeno-associated virus (AAV) = vector technology and manufacturing platforms to develop treatments for cen= tral nervous system and lysosomal storage diseases. Currently, Lacerta is f= ocused on gene therapy solutions for Sanfilippo Syndrome Type B, Friedreich= =E2=80=99s ataxia, Spinocerebellar ataxia, Pompe disease, and Alzheimer=E2= =80=99s. Forward looking statement =E2=80=93 UCB This press release contains forward-looking statements based on current pla= ns, estimates and beliefs of management. All statements, other than stateme= nts of historical fact, are statements that could be deemed forward-looking= statements, including estimates of revenues, operating margins, capital ex= penditures, cash, other financial information, expected legal, political, r= egulatory or clinical results and other such estimates and results. By thei= r nature, such forward-looking statements are not guarantees of future perf= ormance and are subject to risks, uncertainties and assumptions which could= cause actual results to differ materially from those that may be implied b= y such forward-looking statements contained in this press release. Importan= t factors that could result in such differences include: changes in general= economic, business and competitive conditions, the inability to obtain nec= essary regulatory approvals or to obtain them on acceptable terms, costs as= sociated with research and development, changes in the prospects for produc= ts in the pipeline or under development by UCB, effects of future judicial = decisions or governmental investigations, product liability claims, challen= ges to patent protection for products or product candidates, changes in law= s or regulations, exchange rate fluctuations, changes or uncertainties in t= ax laws or the administration of such laws and hiring and retention of its = employees.=C2=A0 UCB is providing this information as of the date of this press release and = expressly disclaims any duty to update any information contained in this pr= ess release, either to confirm the actual results or to report a change in = its expectations. There is no guarantee that new product candidates in the = pipeline will progress to product approval or that new indications for exis= ting products will be developed and approved. Products or potential product= s which are the subject of partnerships, joint ventures or licensing collab= orations may be subject to differences between the partners. Also, UCB or o= thers could discover safety, side effects or manufacturing problems with it= s products after they are marketed. Moreover, sales may be impacted by inte= rnational and domestic trends toward managed care and health care cost cont= ainment and the reimbursement policies imposed by third-party payers as wel= l as legislation affecting biopharmaceutical pricing and reimbursement. Contact information Corporate Communications - UCB Scott Fleming, E: scott.fleming@ucb.com, T: +7702 777 378 Laurent Schots, E: Laurent.schots@ucb.com, T: +32 (0)2 559 92 64 Investor Relations - UCB Antje Witte, E: antje.witte@ucb.com T: +32 (0)2 559 94 14 Contact information =E2=80=93 Lacerta Therapeutics Christina Sarabia, E: christinas@lacertatx.com, T: (1) 386-588-3285 GenericFile UCB Gene therapy press release ENG (https://u7061146.ct.sendgrid.net/ls/cli= ck?upn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6en6pyWaKtUsL47mDeui= AEn-2BQ2OvnAuYmtegHHCUXZjHnTZitz2Ahxha08HGZxWpMt8-3DtraJ_xDPID0vOuylFAU8fv4= e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCO= G9ekocVj-2F2X9c9g1wa7AX2nOjLdtuLJFh1t96PZpeudGCMKgHESdiSWtHQCLvgp4szWoY22W6= E7ZH8PYYDjwAplKHXgXDO2qvXqn-2F0coBhTlEueO-2BIBv6n7Vp5Z6E5VT-2FaIvxW-2B2oJOw= 8QhX0JmOejoeReEXYBwKcI3hYyAA0bf7LRl-2BYhAH7lFVtjP1LY2BDNmvk5eRpAAZ-2BwgP6y1= Wr2AAy7sdwFljLmrZ-2BTgisT-2BjkEOrR3FnEt3-2FrIffwTLPybfM0-2FVxs45EFg2dfE-3D= =0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jAT= UeYfdhr1xEBQnaPhR2RKx1tfe2VKDZTewv5u80JomRcX-2BrUcmFdfVOKEd6zJgXC83-2FFwDHb= Pe2CRzgEbjmB524zZyfkGYEZN5Z0fxEaLqBU2Eh5M8RTO7mTRn1LMt6cGb4eQ8fARAieimOBdiJ= l-2FSUY-3DgPoO_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0Kx= vPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wa7AX2nOjLdtuLJFh1t96PZp= eudGCMKgHESdiSWtHQCLvgp4szWoY22W6E7ZH8PYYDjwAplKHXgXDO2qvXqn-2F0coBhTlEueO-= 2BIBv6n7Vp5Z6PAuluqKw9YDLT98x1t4P-2FDxARJBOD7GOSnvtuD52YmadOhLp0uI-2FjVj1J6= PCzYAhiED6reOgP9Aux-2BWa32lkxzNXcaO7t-2BcSdExNNs-2FhHrCSr7lK2BkvIGSzUSqaPcL= J1yGWbedTKArY2smOnXGeHI-3D=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=


Other stories

28/03/2024 10:05
28/03/2024 07:08
28/03/2024 09:47
27/03/2024 20:43
28/03/2024 10:35
28/03/2024 07:36
28/03/2024 11:11
28/03/2024 03:30
28/03/2024 03:35
28/03/2024 06:00
28/03/2024 03:30
28/03/2024 10:57
28/03/2024 06:35
27/03/2024 20:48
28/03/2024 10:12
28/03/2024 09:59
28/03/2024 08:52
27/03/2024 18:06
27/03/2024 01:33
27/03/2024 16:02
28/03/2024 09:00
27/03/2024 17:30
28/03/2024 10:13
28/03/2024 10:02
28/03/2024 02:39
28/03/2024 10:27
28/03/2024 10:05
28/03/2024 09:11
28/03/2024 03:30
28/03/2024 08:17
27/03/2024 21:46
28/03/2024 09:31
27/03/2024 20:12
26/03/2024 23:17
27/03/2024 23:30
27/03/2024 15:35
28/03/2024 02:42
27/03/2024 18:07